MTOR and osteonecrosis: Subsequently, other drugs, including denosumab and those with antiangiogenic properties—such as tyrosine-kinase inhibitors (TKIs), vascular endothelial growth factor (VEGF) inhibitors, and the mammalian target of rapamycin (mTOR)—have also been linked to the development of osteonecrosis [4–7].